{"id":37715,"date":"2025-07-22T10:55:45","date_gmt":"2025-07-22T02:55:45","guid":{"rendered":"https:\/\/flcube.com\/?p=37715"},"modified":"2025-07-22T10:55:45","modified_gmt":"2025-07-22T02:55:45","slug":"dualitybios-next-generation-her3-adc-db-1310-granted-fda-fast-track-designation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37715","title":{"rendered":"DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation"},"content":{"rendered":"\n

Duality Biologics (HKG: 9606<\/a>) announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3 antibody-drug conjugate (ADC), DB-1310. The designation applies to the treatment of adult patients with advanced\/unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC). This includes patients who have experienced disease progression during or after treatment with third-generation EGFR tyrosine kinase inhibitors and platinum-based chemotherapy, and who have EGFR exon 19 deletion or L858R mutations.<\/p>\n\n\n\n

DB-1310: Next-Generation ADC<\/strong>
DB-1310 is a next-generation HER3-targeted ADC developed by DualityBio using its proprietary DITAC (DNA Topoisomerase Inhibitor-based ADC) technology platform. The drug has shown promising results in the first-in-human Phase I\/IIa clinical study (NCT05785741), demonstrating encouraging efficacy and manageable safety in patients with advanced solid tumors who have failed standard treatments.<\/p>\n\n\n\n

Clinical Progress<\/strong>
The Fast Track Designation underscores the FDA’s recognition of DB-1310’s potential to address significant unmet medical needs in the treatment of nsqNSCLC. This designation is expected to facilitate the development and review process, potentially accelerating the availability of this innovative therapy to patients.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Duality Biologics (HKG: 9606) announced that the US Food and Drug Administration (FDA) has granted…<\/p>\n","protected":false},"author":1,"featured_media":37716,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,232,3974],"class_list":["post-37715","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-duality-biologics","tag-hkg-9606"],"yoast_head":"\nDualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Duality Biologics (HKG: 9606) announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3 antibody-drug conjugate (ADC), DB-1310. The designation applies to the treatment of adult patients with advanced\/unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC). This includes patients who have experienced disease progression during or after treatment with third-generation EGFR tyrosine kinase inhibitors and platinum-based chemotherapy, and who have EGFR exon 19 deletion or L858R mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37715\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation\" \/>\n<meta property=\"og:description\" content=\"Duality Biologics (HKG: 9606) announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3 antibody-drug conjugate (ADC), DB-1310. The designation applies to the treatment of adult patients with advanced\/unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC). This includes patients who have experienced disease progression during or after treatment with third-generation EGFR tyrosine kinase inhibitors and platinum-based chemotherapy, and who have EGFR exon 19 deletion or L858R mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37715\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-22T02:55:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2203.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37715#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37715\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation\",\"datePublished\":\"2025-07-22T02:55:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37715\"},\"wordCount\":194,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37715#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2203.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Duality Biologics\",\"HKG: 9606\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37715#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37715\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37715\",\"name\":\"DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37715#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37715#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2203.webp\",\"datePublished\":\"2025-07-22T02:55:45+00:00\",\"description\":\"Duality Biologics (HKG: 9606) announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3 antibody-drug conjugate (ADC), DB-1310. The designation applies to the treatment of adult patients with advanced\\\/unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC). This includes patients who have experienced disease progression during or after treatment with third-generation EGFR tyrosine kinase inhibitors and platinum-based chemotherapy, and who have EGFR exon 19 deletion or L858R mutations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37715#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37715\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37715#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2203.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2203.webp\",\"width\":1080,\"height\":608,\"caption\":\"DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37715#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation - Insight, China's Pharmaceutical Industry","description":"Duality Biologics (HKG: 9606) announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3 antibody-drug conjugate (ADC), DB-1310. The designation applies to the treatment of adult patients with advanced\/unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC). This includes patients who have experienced disease progression during or after treatment with third-generation EGFR tyrosine kinase inhibitors and platinum-based chemotherapy, and who have EGFR exon 19 deletion or L858R mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37715","og_locale":"en_US","og_type":"article","og_title":"DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation","og_description":"Duality Biologics (HKG: 9606) announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3 antibody-drug conjugate (ADC), DB-1310. The designation applies to the treatment of adult patients with advanced\/unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC). This includes patients who have experienced disease progression during or after treatment with third-generation EGFR tyrosine kinase inhibitors and platinum-based chemotherapy, and who have EGFR exon 19 deletion or L858R mutations.","og_url":"https:\/\/flcube.com\/?p=37715","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-22T02:55:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2203.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37715#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37715"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation","datePublished":"2025-07-22T02:55:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37715"},"wordCount":194,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37715#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2203.webp","keywords":["ADC \/ XDC","Cancer","Duality Biologics","HKG: 9606"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37715#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37715","url":"https:\/\/flcube.com\/?p=37715","name":"DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37715#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37715#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2203.webp","datePublished":"2025-07-22T02:55:45+00:00","description":"Duality Biologics (HKG: 9606) announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3 antibody-drug conjugate (ADC), DB-1310. The designation applies to the treatment of adult patients with advanced\/unresectable or metastatic non-squamous non-small cell lung cancer (nsqNSCLC). This includes patients who have experienced disease progression during or after treatment with third-generation EGFR tyrosine kinase inhibitors and platinum-based chemotherapy, and who have EGFR exon 19 deletion or L858R mutations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37715#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37715"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37715#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2203.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2203.webp","width":1080,"height":608,"caption":"DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37715#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2203.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37715"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37715\/revisions"}],"predecessor-version":[{"id":37717,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37715\/revisions\/37717"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37716"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}